Maker of orthobiologics products, including bone-graft substitutes and hyaluronic-acid injections for joint pain and healing.
Maker of orthobiologics products, including bone-graft substitutes and hyaluronic-acid injections for joint pain and healing.
Sells mainly to orthopaedic and pain clinics, which buy injections such as hyaluronic acid (a lubricating gel put into the knee) and are paid back by insurers, so insurer coverage and surgeon preference matter as much as the clinical case. A bone-healing ultrasound device, Exogen, gives it a second, steadier line.
Moat: narrow (brand, regulatory licence). Established orthobiologics brands with regulatory approvals, though facing generic/biosimilar-style competition.
Headquarters: Durham, North Carolina · Founded: 2012 · Employees: 930
Size Bioventus (BVS) is a United States Health Care company (Medical Specialties) with a market value of $895M, the 2299th largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.62 on 18 Nov 2026.
Performance Over six months the shares fell 2.9%, against -13.6% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 3.9% over the last twelve months (peer median +8.3%); the operating margin is 10.1% (peer median 9.0%).
Valuation It trades at 13.0× forward earnings against a peer median of 22.4× (3rd cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.9 points above its cost of capital (7.8% WACC).
Short interest Short interest is 4.4% of the free float (30 Oct 2026).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $586M | $568M | $573M | $512M | $512M |
| Revenue growth | — | -1% | +12% | 0% | — |
| Gross profit | $398M | $382M | $381M | $319M | $321M |
| EBITDA | $103M | $106M | $100M | $73.4M | $52.8M |
| Net income | $57.3M | $22.7M | -$36.1M | -$156M | -$159M |
| Free cash flow | $84.3M | $71.4M | $36.6M | $7.98M | -$23.6M |
| Capital expenditure | $2.45M | $2.56M | $1.72M | $7.36M | $11.5M |
| Total debt | $244M | $311M | $356M | $409M | $436M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bioventus BVS | $895M | -3% | +4% | 10% | 13.0× | 7.5% |
| Zimmer Biomet ZBH | $19.6B | +21% | +7% | 16% | 11.7× | 7.4% |
| Stryker SYK | $121B | -1% | +8% | 25% | 19.9× | 10.7% |
| Organogenesis ORGO | n/a | -67% | n/a | n/a | n/a | n/a |
| Smith & Nephew SN..L | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BVS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -23.9% | -5.1% | 2nd lowest of 21 |
| 6-month return | -2.9% | -13.6% | 5th highest of 21 |
| Distance from 52-week high | -33.2% | -41.7% | 9th highest of 21 |
| Revenue growth (TTM) | +3.9% | +8.3% | 9th lowest of 21 |
| Operating margin | 10.1% | 9.0% | 9th highest of 21 |
| Forward P/E | 13.0× | 22.4× | 3rd cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 7.5% | 3.3% | 7th most demanding of 14 |
| Growth delivered (Del g) | +12.1% | +11.7% | 7th highest of 14 |
| Hurdle (Req g minus delivered) | -4.6 pp | -4.0 pp | 7th least demanding of 14 |
| ROIC minus cost of capital | +0.9 pp | +2.6 pp | 9th lowest of 21 |
| EV / EBITDA | 11.2× | 9.9× | 4th most expensive of 9 |
| Net debt / EBITDA | 2.1× | 0.3× | 4th most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bioventus BVS | United States | $895M | -3% | +4% | 10% | 13.0× | 7.5% | +12.1% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $888M | -12% | +17% | 18% | 26.2× | 19.3% | +23.3% |
| Artivion AORT | United States | $905M | -18% | +14% | 5% | 383.6× | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $907M | -12% | +41% | 6% | 70.5× | n/a | n/a |
| Shenzhen YHLO Biotech 688575.SS | China | $882M | -16% | +3% | 12% | 30.7× | 2.0% | +12.7% |
| Hangzhou Biotest Biotech 688767.SS | China | $878M | -12% | -4% | 3% | 37.0× | n/a | n/a |
| Xiangyu Medical 688626.SS | China | $877M | -38% | 0% | 4% | 56.2× | n/a | n/a |
| Tinavi Medical Technologies 688277.SS | China | $872M | -36% | -2% | -59% | n/a | n/a | n/a |
| Beijing SDL Technology 002658.SZ | China | $864M | -34% | -13% | 9% | 22.4× | 16.8% | +2.9% |
| HOB Biotech 688656.SS | China | $858M | -33% | +6% | 7% | 166.9× | 37.6% | +12.4% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $858M | -25% | +4% | 30% | n/a | 11.1% | +4.6% |
| L&C BIO 290650.KS | South Korea | $943M | -37% | +65% | 20% | n/a | 32.6% | +21.0% |
| Menicon 7780.T | Japan | $944M | +26% | +6% | 9% | 20.9× | n/a | n/a |
| Modern Dental 3600.HK | Hong Kong | $844M | +24% | +12% | 22% | 8.5× | -7.1% | +11.3% |
| Cisen Pharmaceutical 603367.SS | China | $843M | -15% | -6% | 8% | 7.9× | -14.6% | -1.3% |
| Safilo SFL.MI | Italy | $953M | +42% | -4% | 9% | 15.8× | 1.3% | +4.7% |
| Cofoe Medical Technology 1187.HK | Hong Kong | $836M | -11% | +40% | 10% | 13.1× | -6.4% | +6.6% |
| JINS 3046.T | Japan | $963M | -8% | +14% | 10% | 18.7× | -6.1% | +11.7% |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 19.9× | 3.3% | +13.9% |
| OrthoPediatrics KIDS | United States | $826M | +71% | +16% | -8% | n/a | n/a | n/a |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | n/a | 35.6% | +17.1% |